Compare TTWO & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTWO | A |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1B | 39.8B |
| IPO Year | 1999 | 1999 |
| Metric | TTWO | A |
|---|---|---|
| Price | $208.77 | $111.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 16 |
| Target Price | ★ $283.81 | $161.06 |
| AVG Volume (30 Days) | 1.9M | ★ 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 1.07 |
| Revenue | ★ $5,633,600,000.00 | $4,472,000,000.00 |
| Revenue This Year | $20.49 | $8.42 |
| Revenue Next Year | $36.48 | $6.12 |
| P/E Ratio | ★ N/A | $104.09 |
| Revenue Growth | 5.31 | ★ 6.43 |
| 52 Week Low | $188.56 | $96.43 |
| 52 Week High | $264.79 | $160.27 |
| Indicator | TTWO | A |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 26.36 |
| Support Level | $188.65 | N/A |
| Resistance Level | $221.08 | $122.91 |
| Average True Range (ATR) | 6.55 | 3.02 |
| MACD | 1.23 | -0.42 |
| Stochastic Oscillator | 56.72 | 4.63 |
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.